| 3.74 0.16 (4.47%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.04 | 1-year : | 5.89 |
| Resists | First : | 4.32 | Second : | 5.04 |
| Pivot price | 3.65 |
|||
| Supports | First : | 3.09 |
Second : | 2.33 |
| MAs | MA(5) : | 3.67 |
MA(20) : | 3.45 |
| MA(100) : | 2.44 |
MA(250) : | 1.85 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 53.3 |
D(3) : | 55.2 |
| RSI | RSI(14): 60.1 |
|||
| 52-week | High : | 4.32 | Low : | 0.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ UPC ] has closed below upper band by 38.5%. Bollinger Bands are 20.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.75 - 3.77 | 3.77 - 3.79 |
| Low: | 3.51 - 3.53 | 3.53 - 3.55 |
| Close: | 3.71 - 3.74 | 3.74 - 3.77 |
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Fri, 26 Jul 2024
Post-Trade Analysis: Universe Pharmaceuticals INC (UPC) Slides -0.83, Closing at 3.58 - The Dwinnex
Fri, 26 Jul 2024
Universe Pharmaceuticals (NYSE:UPC) Shares Down 0.8% - Defense World
Thu, 25 Jul 2024
Universe Pharmaceuticals INC (UPC)’s stock rises to 3.61 per share - US Post News
Tue, 23 Jul 2024
UPC’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Mon, 22 Jul 2024
Universe Pharmaceuticals INC's (NASDAQ:UPC) 41% Price Boost Is Out Of Tune With Revenues - Simply Wall St
Thu, 18 Jul 2024
Universe Pharmaceuticals Raises $25 Million in Offering - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 8.8 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 20 (K) |
| EPS | -1.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.9 |
| Profit Margin | -19.1 % |
| Operating Margin | -26.6 % |
| Return on Assets (ttm) | -4 % |
| Return on Equity (ttm) | -14.4 % |
| Qtrly Rev. Growth | -13.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 8.85 |
| EBITDA (p.s.) | -0.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -2.21 |
| PEG Ratio | 0 |
| Price to Book value | 0.34 |
| Price to Sales | 0.42 |
| Price to Cash Flow | 12.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|